The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Cardiomyopathy (acute, subacute, chronic)
Publications
Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges.
Heart, lung & circulation 2022 Feb 10;; — 2022 Feb 10
Schürer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R, Lurz P, Luck M, Hertel P, Schuler G, Linke A, Mangner N
Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy.
JACC. Heart failure 2017 06;5;435-445 — 2017 06 — 435-445
The unique histology of methamphetamine cardiomyopathy: a case report.
Forensic science international 2011 Oct 10;212;e1-4 — 2011 Oct 10 — e1-4
Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology.
Addiction (Abingdon, England) 2008 Aug;103;1353-60 — 2008 Aug — 1353-60
The association of methamphetamine use and cardiomyopathy in young patients.
The American journal of medicine 2007 Feb;120;165-71 — 2007 Feb — 165-71
Cardiomyopathy associated with the smoking of crystal methamphetamine.
JAMA 1991 Mar 06;265;1152-4 — 1991 Mar 06 — 1152-4